Gencurix Inc. (229000) Stock Forecast & Analysis
Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Gencurix Inc. (229000:KRX), powered by AI.
- Current Price
- ₩3,835
- P/E Ratio
- -12.2
- Market Cap
- 89.8B
- Sector
- Healthcare
What is the Gencurix Inc. stock price forecast?
Gencurix Inc. is currently trading at ₩3,835. View real-time AI analysis on Alpha Lenz.
What is Gencurix Inc. insider trading activity?
View the latest insider trading data for Gencurix Inc. on Alpha Lenz.
What is Gencurix Inc.'s P/E ratio?
Gencurix Inc.'s P/E ratio is -12.2.
Gencurix Inc.
KRX · 229000“Gencurix Inc. trades at a P/E of -12.2 (undervalued) with modest ROE of -47.2%. 3Y revenue CAGR of 43.4% highlights clear growth momentum.”
Ask for details →Company Overview
Gencurix Inc. is a biotechnology company specializing in the development and commercialization of innovative diagnostic solutions across the globe. The primary function of Gencurix is to provide reliable and efficient molecular diagnostic tests, particularly focusing on genetic assays that aid in cancer prognosis and treatment decision-making. Notable among its offerings is the "GenesWell™" system, which offers tests like the "GenesWell BCT," designed for breast cancer patients. This system plays a crucial role in personalized medicine by helping physicians tailor treatment plans according to genetic markers, thus enhancing patient outcomes. Gencurix Inc. impacts the healthcare sector significantly, as it supports a more targeted approach to cancer treatment, which contributes to advancements in oncology. Its role in the market is strengthened by the growing demand for precision medicine, where accurate and early diagnosis is pivotal. As biotechnology continues to evolve, Gencurix is poised at the intersection of molecular technology and therapeutic innovation, serving as a critical player in improving global health diagnostics.
Company Statistics
FY 2025Profile
Margins
Valuation
Growth (CAGR)
Returns
Financial Health
“Gencurix Inc. trades at a P/E of -12.2 (undervalued) with modest ROE of -47.2%. 3Y revenue CAGR of 43.4% highlights clear growth momentum.”
Ask for details →Frequently Asked Questions
Gencurix Inc. (ticker: 229000) is a company listed on KRX in the Healthcare sector (Diagnostics & Research). It has approximately 69 employees. Market cap is $89.8B.
The current price is ₩3,835 with a P/E ratio of -12.16x and P/B of 5.49x.
ROE is -47.25% and operating margin is -78.83%. Annual revenue is $7.5B.